Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Diversity of Antigen Receptors01:28

Diversity of Antigen Receptors

2.0K
Antigen receptors are essential components of the immune system crucial in defending the body against foreign invaders. These receptors are present on the surface of B and T cells, enabling them to recognize antigens and mount an appropriate immune response.
Before encountering any antigen, lymphocytes express these receptors. On B cells, the antigen receptor is a membrane-bound antibody molecule called BCR; on T cells, it is a T cell receptor or TCR. B and T cell receptors are composed of two...
2.0K
T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

17.0K
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
17.0K
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

70
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
70
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

4.7K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.7K
Tumor Immunotherapy01:27

Tumor Immunotherapy

2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Special Features of Adaptive Immunity01:20

Special Features of Adaptive Immunity

3.9K
The adaptive immune system, a crucial component of the overall immune response, offers a highly specialized defense against pathogens. It involves specific cell types and features, enabling it to combat infections effectively and efficiently.
The primary cell types involved in adaptive immunity are T cells and B cells. Each type has a unique role in defending the body against pathogens. T cells are responsible for cell-mediated immunity. They identify and eliminate infected cells directly,...
3.9K

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

A phase 1 trial of HPV16 E7 T-cell receptor-engineered T cells in patients with relapsed/refractory HPV16-positive cancers (KITE-439 trial).

Frontiers in oncology·2026
Same author

HLA micropolymorphisms confine neoantigen conformational adaptability and guide T cell receptor selectivity.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Cancer type-specific variation in patterns of driver alterations across 50,000 tumors.

Cancer cell·2026
Same author

Mitochondrial ATP production promotes T cell differentiation and function by regulating chromatin accessibility.

bioRxiv : the preprint server for biology·2026
Same author

Cancer type-specific variation in patterns of driver alterations across 50,000 tumors.

Cancer cell·2026
Same author

A post-translational regulatory map of chronic antigen-driven human T cell dysfunction.

bioRxiv : the preprint server for biology·2026
Same journal

A viral ORFeome library for systems-level genetic dissection of host-pathogen interactions.

Cell·2026
Same journal

Co-option of lysosomal machinery shapes the evolution of the intracellular photosymbiosis supporting coral reefs.

Cell·2026
Same journal

LEF1 and niche factors determine T cell stemness across chronic diseases.

Cell·2026
Same journal

Recurrent patterns of TOP1-mediated neuronal genomic damage shared by major neurodegenerative disorders.

Cell·2026
Same journal

Four-dimensional molecular mapping from a spatial snapshot reveals the dynamics of hair follicle organogenesis.

Cell·2026
Same journal

Whole-cell particle-based digital twin simulations from 4D lattice light-sheet microscopy data.

Cell·2026
関連記事をすべて見る

関連する実験動画

Updated: Mar 14, 2026

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates
06:10

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

1.0K

受容器設計のT細胞の機能とペイロード配信のカスタマイズ

Christopher A Klebanoff1, Nicholas P Restifo2

  • 1Center for Cell Engineering and Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

Cell
|October 8, 2016
PubMed
まとめ
この要約は機械生成です。

アドプティブ・イムノセラピーは 癌の治療に有望である. 新しい研究は T細胞の腫瘍標的化と 副作用の軽減の 明確な戦略を提示し 癌治療を進めています

さらに関連する動画

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

16.1K
Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood
09:29

Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood

Published on: February 1, 2013

19.0K

関連する実験動画

Last Updated: Mar 14, 2026

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates
06:10

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

1.0K
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

16.1K
Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood
09:29

Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood

Published on: February 1, 2013

19.0K

科学分野:

  • 免疫学
  • 腫瘍学
  • バイオテクノロジー

背景:

  • アドプティブ・イムノセラピー,特にT細胞ベースの治療は,がん治療における重要な進歩を表しています.
  • 特定の受容体を持つT細胞の設計は,腫瘍の標的化と治療効果を改善することを目的としています.
  • 強化されたT細胞活動に関連した潜在的な毒性は,よりよい制御のための戦略を必要とします.

研究 の 目的:

  • 養子免疫療法の改善のための2つの異なるアプローチを提示する.
  • エンジニアリングされたT細胞の腫瘍特異性を高める方法を強調します.
  • T細胞療法による潜在的な悪影響を軽減するための戦略に取り組む.

主な方法:

  • 2つの独立した研究の結果のレビューと要約 (Boice et al. ロイバルなど ) でした.
  • T細胞ターゲティングのための受容体工学技術の分析
  • T細胞の活動と毒性を制御するための方法の評価

主要な成果:

  • 採用免疫療法を強化するための2つの異なる,潜在的に補完的な戦略が特定されました.
  • これらのアプローチは,腫瘍標的の精度を向上させ,治療に関連する毒性を管理することに焦点を当てています.
  • この研究は 癌に対するT細胞治療の最適化に 新しい洞察力をもたらします

結論:

  • 遺伝子組み換えT細胞治療は 癌の治療に非常に有望です
  • 採用免疫療法の有効性と安全性の両方を向上させる機会を提供している.
  • これらのアプローチに関するさらなる研究は より効果的で安全ながん治療に繋がるかもしれません